PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT01162681. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT01162681
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Enrollment
- 547 participants
Conditions and interventions
Conditions
Interventions
- A-623 Drug
- Placebo Comparator Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2010
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
- Last update posted
- Mar 3, 2014
2010 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 103 | Birmingham | Alabama | 35294 | — |
| Investigator Site 113 | Long Beach | California | 90806 | — |
| Investigator Site 108 | Los Angeles | California | 90095 | — |
| Investigator Site 110 | Upland | California | 91786 | — |
| Investigator Site 105 | Orlando | Florida | 32806 | — |
| Investigator Site 102 | Tampa | Florida | 33614 | — |
| Investigator Site 117 | Baltimore | Maryland | 21205 | — |
| Investigator Site 104 | Lansing | Michigan | 48910 | — |
| Investigator Site 106 | Lake Success | New York | 11042 | — |
| Investigator Site 114 | Smithtown | New York | 11787 | — |
| Investigator Site 101 | Greenville | North Carolina | 27834 | — |
| Investigator Site 112 | Oklahoma City | Oklahoma | 73104 | — |
| Investigator Site 111 | Tulsa | Oklahoma | 74104 | — |
| Investigator Site 115 | Houston | Texas | 77034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01162681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2014 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01162681 live on ClinicalTrials.gov.